Dr. Rosenthal is a Professor of Microbiology & Immunology, as well as Director of MS and Certificate programs in Biohazardous Threat agents & Emerging Infectious Diseases
- Ph.D., Kansas State University, 1969
- At Georgetown Since: 1975
- Contact: (202) 687-1140; firstname.lastname@example.org
Dr. Rosenthal is an AIDS/cancer researcher who has focused on the association of herpesviruses with human cancer and AIDS. In September, 2002, Dr. Rosenthal, along with Dr. Lucey, co-organized the first GU/MedStar Workshop on Bioterrorism attended by over 500 students. Drs. Rosenthal and Lucey have previously co-organized a biodefense program as part of the Mini Medical School series for faculty, staff, and students and the community at large. Dr. Rosenthal is Director of the MS program in Biohazardous Threat Agents & Emerging Infectious Diseases as well as Director of the Online Certificate program in Biohazardous Threat Agents & Emerging Infectious Diseases and Co-Director of the resident certificate program in Biodefense & Public Policy.
- Gallagher RM, Rosenthal LJ. Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil. 2008 Mar;89(3 Suppl 1):S77-82. Review
- Rosenthal LJ, Kim V, Kim DR. Weaning from prolonged mechanical ventilation using an antipsychotic agent in a patient with acute stress disorder. Crit Care Med. 2007 Oct;35(10):2417-9.
- Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J Virol. 2007 Dec;81(24):13544-51. Epub 2007 Oct 3.
- Ifon, E., Pang,A., Johnson,W., Cashman, K., Zimmerman,S., Muralidhar, S., Chan, W-Y., Casey, J., and Rosenthal,L. U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int. 2005 Jun 22;5:19.
- Curreli, F., Cerimele, F., Muralidhar,S., Rosenthal, L.J., Cesarman, E., Friedman-Kien, A , Flore, O., Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. J Virol. 2002 May;76(10):5208-19.
- Muralidhar, S., Veystmann, G., Chandran, B., Ablashi, D., Doniger, J., and Rosenthal, L.J. 2000. Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, Kaposin (ORFK12). J. Clin. Virol. 16:203-213.
- Muralidhar, S., and Rosenthal L.J. Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, kaposin (ORF K12). J Clin Virol. 2000 May;16(3):203-13.
- Doniger, J., Muralidhar, S., and Rosenthal, L.J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev. 1999 Jul;12(3):367-82. Review.
- Muralidhar, S., Pumfery, A.M., Hassani, M., Sadaie, M.R., Kishishita, M., Brady, J.N., Doniger, J., Medveczky, P., and Rosenthal, L.J. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol. 1998 Jun;72(6):4980-8. Erratum in: J Virol 1999 Mar;73(3):2568.
- Araujo, J.C., Doniger, J., Stoppler, H., Sadaie, M.R., and Rosenthal, L.J. Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation. Oncogene. 1997 Feb 27;14(8):937-43.